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Objective: Radiation therapy has gained significant attention for the treatment and prevention of solid and malignant human tumors. However, 
after periodical exposures, radiation therapy losses its efficacy against cancer cells displaying radio-resistant phenotypes. Therefore, decursin might 
improve the efficiency of radiotherapy against a variety of human cancers.
Methods: The chemopreventive efficacy of decursin was evaluated against B16F10 cancer cell lines and DMBA/croton oil-induced skin carcinogenesis 
in BALB/c mice. Decursin was administered intraperitoneal at the dose of 20 mg/kg/day for 8 weeks following exposure to 5 Gy of ionizing radiation 
(IR) after 1 month of DMBA application. Western blot was performed for underlying mechanism of radioresistance.
Results: Decursin suppressed the proliferation and viability of melanoma cancer cell lines in a concentration- and time-dependent manner. The in vivo 
data collected from mice model revealed that decursin reduced the precancerous skin lesions and the incidence of tumor bearing in radiation-exposed 
mice. Decursin also enhanced the effect of IR by downregulation of Akt/NFκB pathway through activation of IκBα.
Conclusion: Our results suggest that the activation of Akt/NFκB establishes a pro-survival response to radiation that may account for the development 
of radioresistance. Decursin blocks the abnormal expression of these proteins and potentiates the radiotherapeutic effect.
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INTRODUCTION
Ionizing radiation (IR) is an established beneficial treatment modality 
for the treatment of pre- and post-operative cancer, which selectively 
target and destroy cancer cells [1]. Radioresistance is a biological 
phenomenon which limits and decreases the maximal therapeutic 
efficacy of radiotherapy for the treatment of tumors [2]. Among various 
human cancers, melanoma has been believed to be a radio-resistant 
tumor type as compared to other types of cancers [3]. Studies have 
reported various plant isolated compounds for radiosensitization 
as well as radioprotection [4]. Therefore, low cost and less toxic 
radiosensitizers are urgently required, which can reduce the radiation 
dose–response threshold for cancer cells and provide radioprotection 
to normal cells [4].
PI3k/Akt pathway has been involved in tumor cell proliferation and 
intrinsic radioresistance [5]. In melanoma, aberrant activity of the PI3k/
Akt pathway has been demonstrated to promote melanogenesis [5]. 
A number of studies have shown that specific inhibition of PI3k/
Akt/mTOR pathway has enhanced the radiosensitivity of various 
cancer cell lines both in vitro and in vivo [6]. On activation, PI3k/Akt 
pathway also regulates the expression of downstream targets such as 
NFκB, which further potentiates the process of radioresistance. NFκB 
activation constitutively leads to radioresistance. Inhibition of NFκB 
activation can lead to an increase in the efficacy of radiation therapy [7]. 
Therefore, downregulation of NFκB is a promising target to enhance 
radiosensitivity [7].
Decursin is a naturally occurring coumarin compound isolated from 
the roots of Korean Angelica also known as Angelica gigas Nakai [8]. 
Decursin exerts its anticancer effects by inducing apoptosis through 
activation of caspase 8, 9, and 3, downregulation of antiapoptotic 
proteins such as Bcl-2 and Bcl-xL, by inhibiting vascular endothelial 
growth factor (VEGF)-induced angiogenesis, by inducing cell cycle 
arrest through the downregulation of cyclin D1, and by modulating 
various signaling pathways including NFκB and PI3K pathways [9,10].
Previously, we have summarized and reported the anti-inflammatory 
and synergistic role of decursin in various cancers [11]. In the current 
study, we have investigated the role of decursin in modulating the 
radioresponse of melanoma cancer in vitro and in vivo. Decursin 
enhanced radiosensitization through downregulation of NFκB and 
PI3K.
METHODS
Cell culture and treatment
B16F10 cells of Mus musculus skin melanoma were obtained from 
ATCC, CRL-6475™. Cells were cultured at a density of 5×105 in RPMI-
1640 medium containing 10% heat-inactivated fetal bovine serum, 
L-glutamine and supplemented with 1% (v/v) antibiotic-penicillin 
streptomycin (Gibco, Invitrogen Corporation) at 37°C in a 5% CO2-
humidified atmosphere. 70% confluent growing cells were seeded at 
1×106 cells per dish followed by exposure to various concentrations 
(2, 5, 10, 20, 40, 80, and 100 µM) of decursin (≥97% Sigma-Aldrich, 
USA). For 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT) assay, cells were exposed to various concentrations 
of decursin for next 24 h. After this, medium was removed and 50 µl 
of MTT solution (5 mg/mL in phosphate-buffered saline) was added 
to each well. After 3 h, the MTT solution was removed and 200 µl of 
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dimethyl sulfoxide was added and analyzed by microplate reader 
(BioTek, USA) at 570 nm in a triplicate.
Experimental design
BALB/C male mice (27–30 g, 5–6 weeks) were purchased from the 
National Institute of Health (NIH, Islamabad, and were divided into 
four groups, each containing six mice. Our experimental protocol was 
approved by the Institutional Animal Care and Ethics Committee, in line 
with international laws and policies (NIH Guide for the Care and Use of 
Laboratory Animals, NIH publication No. 85–23, 1985). These groups 
were assigned to different treatments as follows: Group A (DMBA/
Croton oil): The animals in this group received topical applications of 
DMBA in acetone (100 μL) at a dose of 400 nmol per application at an 
interval of 72 h per mouse. Starting from the 8 days after the first DMBA 
application, croton oil (1% w/v) in acetone (100 µL) was applied twice 
in a week for a total of 8 weeks. Group B mice were exposed to 5 Gy/
month of IR after induction of tumor with DMBA/croton oil. Group C 
(decursin 20 mg/kg ip injection): The animals in this group were 
applied with DMBA/croton oil following concomitant treatment with ip 
injection of decursin. Group D received decursin and IR after treatment 
with DMBA/croton oil. During the 8 weeks of experimental period, the 
animals were observed daily for the appearance of skin papillomas and 
the tumor volume was recorded. At the start of 9 weeks, all the mice 
were sacrificed and the skin samples were collected.
Western blotting
In brief, proteins were extracted from the developed tumor of different 
treatment groups through tissue lysis buffer. Proteins were transferred 
onto nitrocellulose membranes (0.2 μM, Schleicher and Schuell). 
Membranes were blocked using 5% non-fat dry milk and probed with 
primary antibody in TBS containing 3% non-fat dry milk and 0.1% 
Tween 20. Antibodies in the ratio of 1:1000 v/v were used and detected 
using an enhanced chemiluminescence kit (Amersham Corp).
RESULTS
Decursin inhibited B16F10 cells proliferation
Cell viability assay determines the inhibitory concentration of the drug, 
which has therapeutic effect. B16F10 cell lines were treated with various 
concentrations (0–100 µM) of decursin. As shown in Fig. 1a, decursin 
reduced the cells viability of B16F10 cells in a concentration-dependent 
manner. Furthermore, we checked the time-dependent effects of 40 μM 
of decursin various time periods. Decursin significantly reduced 
the cells viability after 12 h (Fig. 1b). These results demonstrate the 
therapeutic potential of decursin in vitro against melanoma cell lines.
Decursin reduced DMBA-induced tumor in BALB/C
We evaluated the combined effects of decursin and IR against 
the growth of DMBA-induced tumor model. As shown in Fig. 2, 
combined administration of decursin and IR reduced the tumor 
growth as compared to their individual effect. Tumor volume was 
measured according to the formula: V = 4/3πW2L (short size2×long 
size/2 (mm3). The mice were sacrificed for the isolation of tumor after 
the 8th week.
Decursin inhibited the DMBA-induced expression of NFκB and Akt
In our study, DMBA treatment activates Akt and NFkB, whereas degrad 
IkB (Fig. 3). However, decursin treatment reversed the carcinogenic 
and tumorigenic effect of DMBA. Decursin potentiated the effects of IR 
in DMBA-induced tumor (Fig. 3). One of the known activators of IKK 
signaling pathway is Akt, which also mediates radioresistance through 
induction of pro-survival signaling. Decursin significantly inhibited 
DMBA-induced Akt and NFκB (Fig. 3).
DISCUSSION
Skin cancers are counted among curable cancers, but the development 
of resistant phenotype makes it hard to treat with standard chemo 
and radiotherapy [12,13]. The study was conducted to investigate the 
radiosensitizing effect decursin in DMBA-induced carcinoma. For this 
purpose, B16F10 cells and carcinogen model were exposed to decursin 
and IR. Decursin reduced the cells viability in a concentration- and time-
dependent manner. Decursin reduced the cancer lesions in squamous 
cell carcinoma and potentiated the effect of IR in DMBA-induced tumor 
model. The previous studies have shown that activation of Akt and 
NFκB provides a pro-survival response to radiation that may account 
for the development of radioresistance [14,15]. Decursin activates 
IKBα and inhibits Akt/NFκB pathway and boosts the efficacy of 
radiotherapy.
Fig. 1: (a) Concentration0dependent effect of decursin against B16F10 cell lines. (b) Time-dependent effect of 40 µL of decursin against 
B16F10 cell lines. p≤0.05
Fig. 2: Decursin sensitizes DMBA-induced tumors to radiation in 
BALB/C mice. Decursin and IR together reduced tumor size as 
compared to their individual treatments. Tumor volumes were 
measured using Vernier calipers, calculated as described in 
materials and methods. p≤0.05 (n=6)
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There is accumulating evidence that PI3k/Akt and NFκB signaling 
pathways are involved in radioresistance [12,14]. Activation of Akt 
causes downregulation of tumor suppressor gene phosphatase 
and tensin homolog and inhibits the process of apoptosis [16,17]. 
Furthermore, Akt has been reported to phosphorylate the NFκB, 
increasing the transcription of NFκB downstream targets involved in 
cancer development and therapeutic resistance [18,19]. Therefore, 
inhibition of Akt will suppress the activation of NFκB in malignant 
melanoma cells [18]. Decursin treatment decreased the expression of 
p52 subunit of NFκB in a DMBA-treated group. The expression of IκB 
was also increased in the decursin-treated group. Our results indicate 
that decursin has the ability to block Akt and NFκB activation in DMBA-
induced tumor model. Decursin can provide alternate strategy to 
potentiate the therapeutic effect of IR.
The underlying mechanism of tumor resistance is mediated through 
multiple interrelated signal transduction pathways. Deep understanding 
of these multiple molecular processes underlying resistance to cancer 
therapeutics has led to the demand for the less toxic and cost-effective 
novel agents [20,21]. 
CONCLUSION
Decursin has the ability to reduce the cells viability of B16F10 cells in 
a concentration- and time-dependent manner. Decursin also enhances 
the effect of IR by downregulating the expression of Akt/NFκB, which 
is involved in cancer cells survival and radioresistance. Therefore, 
decursin-induced radiosensitization may have potential therapeutic 
effect in cancer radiotherapy.
Further in vitro and in vivo studies are needed to investigate the 
molecular mechanism of decursin in various cancers to further 
advocate the radiosensitizer role. Furthermore, pharmacodynamics, 
pharmacokinetics, and safety studies of decursin are further needed to 
confirm the detail mechanism of action with optimum dose and dosage 
form in cancer chemotherapy.
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Fig. 3: Decursin suppressed the expression of NFκB and Akt in 
DMBA-induced tumor mice. Developed tumors were isolated, 
homogenized and total protein was isolated from cells and 
analyzed by western blotting. Actin was used as a loading control
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